• SELECT SITE CURRENCY
Select a currency for use throughout the site
Qatar Pharmaceuticals and Healthcare Report Q2 2012
Business Monitor International, March 2012, Pages: 78
BMI View: Following Qatar’s decision to reintroduce controls on medicine prices in late 2011, we expect pharmaceutical price inflation to moderate. Consequently, market growth rates in 2012 will be at their lowest levels for several years. Having said this, strong demand for high-value medicines and a favourable risk profile will remain attractions for drugmakers.
Headline Expenditure Projections
- Pharmaceuticals: QAR1.42bn (US$390mn) in 2011 to QAR1.55bn (US$426mn) in 2012; +9.2% in local currency and US dollar terms.
- Healthcare: QAR11.17bn (US$3.07bn) in 2011 to QAR12.36bn (US$3.40bn) in 2012; +10.7% in local currency and US dollar terms.
- Medical devices: QAR1.02mn (US$279mn) in 2011 to QAR1.18mn (US$325mn) in 2012; +16.4% in local currency and US dollar terms.
Risk/Reward Rating: In BMI’s Q212 Risk/Reward Ratings (RRRs) for the Middle East and Africa (MEA) region, Qatar came third out of the 30 countries assessed. Only the UAE scored higher for the risks category, which demonstrates Qatar’s favourable market and country structure, including a predictable operating environment and a sound economic base. On the other hand, its score for the rewards category is dragged down by a small and a relatively young population, despite high per capita spending on pharmaceuticals.
Key Trends And Developments
- At the beginning of 2012, the Qatar Council for Health Practitioners (QCHP) was established as the new authority to regulate the licensing of healthcare practitioners in private sector and government hospitals in the country. The government approved the QCHP to replace the medical licensing department of the Supreme Council of Health (SCH). The QCHP will have the power to license and monitor all healthcare practitioners in the private and public sectors once it is fully operational.
BMI Economic View: We believe that consumer price inflation in Qatar is likely to accelerate more rapidly in 2012 than was the case in 2011. Data from the Qatar Statistics Authority (QSA) show inflation falling to 2.2% year-on-year (y-o-y) in November, compared with 2.4% in October. Nevertheless, we expect the medium-term trend of rising inflation to persist throughout 2012, as rapid economic growth continues and generous public sector pay hikes filter through to the broader economy.
BMI Political View: The Middle East and North Africa (MENA) will remain a volatile region in 2012 as political transitions continue and several key economies face increasing risks of a currency crisis. Growth in the oil-rich Gulf will continue to outperform, supported primarily through loose fiscal policies. For investors, a growing concern will be increasingly unpredictable policy formation. We also reiterate our long-held view that there is nothing inherent in the Arab Spring that will bring about a more businessfriendly climate.
Business Monitor International's Qatar Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Qatar's pharmaceuticals and healthcare industry.
Qatar Pharmaceuticals And Healthcare Industry SWOT
Qatar Political SWOT
Qatar Economic SWOT
Qatar Business Environment SWOT
Pharmaceutical Risk/Reward Ratings
Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q212
Qatar – Market Summary
Regional Regulatory Developments
Intellectual Property Regime
Pricing And Reimbursement Regime
Regional Price Harmonisation
Table: Diabetes Prevalence In Gulf States (% of total population)
Healthcare Sector Developments
Research And Development
Medical Devices Industry
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales, 2008-2016
Key Growth Factors – Industry
Table: Overall Healthcare Expenditure, 2008-2016
Table: Governmental Healthcare Expenditure, 2008-2016
Table: Private Healthcare Expenditure, 2008-2016
Key Growth Factors – Macroeconomic
Table: Qatar Economic Activity, 2011-2016
Prescription Drug Market Forecast
Table: Prescription Drug Sales, 2008-2016
Patented Drug Market Forecast
Table: Patented Drug Sales, 2008-2016
Generic Drug Market Forecast
Table: Generic Drug Sales, 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales, 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales, 2008-2016
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade, 2008-2016
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecasts
Pharmacy Wholesale And Retail
Qatari German Company For Medical Devices (QGMD)
Ebn Sina Medical
Merck & Co
Country Snapshot: Qatar Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market and Spending Power
Table: Employment Indicators, 2001-2004
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Manufacturing Wages, 2001-2005
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Indicators
Table: Weighting Of Components
- Qatari German Company For Medical Devices (QGMD)
- Medicare Group
- Ebn Sina Medical
- Merck & Co
A sample for this product is available. Please Login/Register to download this sample.